ArticleFrontiers in oncology2026

Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy.

Maria Carlsen Melander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.